SUSD2 Deletion in CD8+ T Cells for Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, such as immune checkpoint blockade, face challenges in achieving durable clinical responses due to immunosuppressive tumor microenvironments, particularly the decline of immune function in CD8+ T cells, and the complexity of multiple immune checkpoint molecules, which limits the effectiveness of targeting a single molecule.
Innovation Solution
Genetically modified cells with a deletion of the SUSD2 gene, specifically in CD8+ T cells, are used in combination with anticancer agents like PD-L1 or PD-1 antibodies to enhance antitumor immunity by overcoming the immunosuppressive effects and improving the effector functions of CD8+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade is used to treat cancer, then immune response is activated, but immunosuppressive tumor microenvironment limits durable clinical response
Solution Approach 1:
The patent segments the immune checkpoint blockade approach by identifying and targeting specific molecules (SUSD2, PD-1, PD-L1) within the broader immune checkpoint system. By dividing the complex immunosuppressive network into discrete targetable components, the therapy can more effectively overcome the tumor microenvironment's suppression without being overwhelmed by the complexity of the entire system.
Solution Approach 2:
The patent changes the therapeutic parameter from single-checkpoint blockade to combined blockade of multiple checkpoints (SUSD2 + PD-1/PD-L1). This parameter change in the treatment approach allows simultaneous overcoming of multiple immunosuppressive pathways, thereby achieving durable clinical response despite the immunosuppressive tumor microenvironment.
2Adaptability or versatility
If multiple immune checkpoint molecules are present, then immune regulation is maintained, but targeting a single molecule cannot override compensatory signals
Solution Approach 1:
The patent merges multiple checkpoint blockade strategies by combining SUSD2 targeting with PD-1/PD-L1 blockade. This combination approach allows the therapy to simultaneously address multiple immune checkpoint molecules, overriding compensatory signals that would otherwise limit the effectiveness of single-molecule targeting while maintaining proper immune regulation.
3Reliability
If CD8+ T cell effector function is suppressed in tumor microenvironment, then tumor growth is controlled, but cancer patients show resistance to ICB treatment
Solution Approach 1:
The patent applies preliminary action by using SUSD2 targeting to pre-condition and enhance CD8+ T cell effector functions before administering PD-1/PD-L1 blockade. This preliminary enhancement of T cell function ensures that when the PD-1/PD-L1 pathway is blocked, the CD8+ T cells are already primed and capable of mounting an effective anti-tumor response, thereby overcoming resistance to ICB treatment.
Solution Approach 2:
The patent introduces SUSD2 as an intermediary target that mediates the enhancement of CD8+ T cell function. By blocking SUSD2, the therapy indirectly restores T cell effector functions, which then enables more effective response to PD-1/PD-L1 blockade. This intermediary approach addresses the decline of immune function in CD8+ T cells while improving overall ICB treatment efficacy.
Data Source
AI summary
The present disclosure relates to the field of T cell-based immunotherapy to promote anti-cancer effector functions.